We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Summary/transcript
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
Dr Ryll believes that educating and communicating these changes in therapy to patients is a challenge. She also points out that patients who are educated and have good knowledge of their disease and treatment, fare better than patients who do not have this knowledge.
Therefore, the Melanoma Patient Network Europe has a heavy focus on education for patients in order to improve outcome. Dr Ryll also highlights the importance of working together with oncologists to achieve this.
We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed. Brandcast Health
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. Brandcast Health
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. Brandcast Health
Shafi Ahmed, PhD, FRCS, Director of Virtual Medics and Medical and GIANT Event Co-chair, provides an overview of the GIANT Health Event. Brandcast Health